EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

A prospective, randomized, open‐label, parallel trial comparing the efficacy of α‐blocker or 5α‐reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia

Kwang Suk Lee iD, Jeong Woo Yoo, Dae Ho Kim, Soyoung Jeon, Juyeon Yang, Byung Ha Chung, Kyo Chul Koo iD

The Prostate · 2024

DOI: 10.1002/pros.24663 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Prostate, 2024. Verfasst von Kwang Suk Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Urinary Retention. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Handok Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It is uncertain how long combination therapy should be continued in patients with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). We investigated the withdrawal effects of α1‐adrenergic receptor blocker (AB) or 5α‐reductase inhibitor (5ARI) following successful combination therapy.

Methods

This prospective, randomized, open‐label, parallel trial enrolled 222 patients with BPH/LUTS who showed at least a seven‐point improvement in International Prostate Symptom Score‐total (IPSS‐T) and a ≥ 20% reduction in prostate volume (PV) following the initiation of combination therapy. Patients were randomized in a 1:1:1 ratio into continued‐combination, AB‐withdrawal, and 5ARI‐withdrawal groups. IPSS, overactive bladder symptom score, EuroQol‐five‐dimensional questionnaire (EQ‐5D‐5L), EuroQol‐visual analog scale (EQ‐VAS), prostate volume (PV), maximal flow rate, postvoid residual urine (PVR), and prostate‐specific antigen level were assessed every 6 months for 24 months. The predictors of IPSS‐T deterioration were evaluated.

Results

At Month 24, IPSS‐T deterioration (≥2 point) was observed in 20/72 (27.8%) and 19/72 (26.4%) patients in the AB‐ and 5ARI‐withdrawal groups, respectively. Among them, 4/72 (5.6%) and 4/70 (5.7%) patients required readdition of the withdrawn drug ( p = 0.868). In the continued combination group, EQ‐VAS improved at Month 24 compared to baseline ( p = 0.028). At Month 24, the AB‐withdrawal group showed improvements in EQ‐5D‐5L, EQ‐VAS, and PVR (all p < 0.005), while the 5ARI‐withdrawal group showed improvement in IPSS‐S ( p = 0.011). Diabetes mellitus was associated with IPSS‐T deterioration at Month 24 ( p = 0.020).

Conclusions

In patients with BPH/LUTS who are reluctant to continue combination therapy, AB or 5ARI withdrawal may be offered in men with improvement in IPSS‐T by at least seven points and reduction in PV by at least 20%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaLower Urinary Tract SymptomsUrinary RetentionMaleHumansProspective StudiesDrug Therapy, Combination5-alpha Reductase InhibitorsAdrenergic alpha-AntagonistsOxidoreductasesTreatment Outcome

Stichwörter der Autor:innen

5-alpha reductase inhibitorsadrenergic alpha-1 receptor antagonistslower urinary tract symptomsprostatic hyperplasia

Substanzen

5-alpha Reductase InhibitorsAdrenergic alpha-AntagonistsOxidoreductases

Autor:innen und Institutionen

  • Department of Urology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Biostatistics Collaboration Unit, Medical Research Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Kwang Suk Lee, Kyo Chul Koo

Förderung

  • Handok Pharmaceuticals

Zitieren

APA

Lee, K. S., Yoo, J. W., Kim, D. H., Jeon, S., Yang, J., Chung, B. H., & Koo, K. C. (2024). A prospective, randomized, open‐label, parallel trial comparing the efficacy of α‐blocker or 5α‐reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia. The Prostate. https://doi.org/10.1002/pros.24663

Vancouver

Lee KS, Yoo JW, Kim DH, Jeon S, Yang J, Chung BH, et al. A prospective, randomized, open‐label, parallel trial comparing the efficacy of α‐blocker or 5α‐reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia. The Prostate. 2024. doi:10.1002/pros.24663

BibTeX
@article{Lee2024,
  author = {Lee, Kwang Suk and Yoo, Jeong Woo and Kim, Dae Ho and Jeon, Soyoung and Yang, Juyeon and Chung, Byung Ha and Koo, Kyo Chul},
  title = {A prospective, randomized, open‐label, parallel trial comparing the efficacy of α‐blocker or 5α‐reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24663}
}
Kostenlos starten →